摘要
β-内酰胺酶抑制剂对各种革兰阳性菌、革兰阴性菌、厌氧菌等所产生的β-内酰胺酶均有广泛的抑制作用,临床研究确认其与β-内酰胺类抗生素的复合制剂用于呼吸系统、腹腔、皮肤和软组织等感染的经验治疗有效,用于中性粒细胞减少的发热、院内感染也有效。β-内酰胺类抗生素/β-内酰胺酶抑制剂复合制剂治疗混合感染特别有效,用于多重耐药菌如不动杆菌属和嗜麦芽窄食单胞菌所致感染治疗亦在增加。本文简要介绍β-内酰胺酶抑制剂的发展和开发近况。
β-Lactam/β-lactamase inhibitor is able to inactivate a wide range of β-lactamases produced by Gram-positive,Gram-negative,anaerobic and even acid-fast pathogens.Clinical experience confirms their efficacy in the empirical treatment of respiratory tract,intra-abdomina,and skin and soft tissue infections.There is evidence to suggest that they are effective in treatment of patients with neutropenic fever and nosocomial infections.β-Lactam/β-lactamase inhibitor combinations are particularly effective to treat patients with mixed infections.β-Lactamase inhibitors have gained more and more importance in treating various multi-resistant pathogens such as Acinetobacter species and Stenotrophomonas maltophilia.This review gives us a brief introduction of the research and development of β-lactamase inhibitors.
出处
《上海医药》
CAS
2011年第5期222-226,共5页
Shanghai Medical & Pharmaceutical Journal
